Pain after percutaneous radiofrequency ablation of renal tumors

Meredith Baker, J. Kyle Anderson, Omar Jaffer, Clayton K Trimmer, Jeffrey A Cadeddu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and Purpose: Most patients have minimal pain after percutaneous radiofrequency ablation (RFA) of a renal tumor. However, anecdotally, there is some variation in the amount of patient discomfort. Our goal was to identify relevant patient factors and characteristics of their renal tumors that may influence pain after percutaneous RF ablation. Patients and Methods: We performed a retrospective chart review of 59 sequential patients who received percutaneous RFA between 2001 and 2005 at a single institution. Data on patient age, sex, body mass index (BMI), and narcotic administration in the periprocedural period were available for 46 patients. Preoperative imaging (CT or MRI) was reviewed to determine tumor size and location, as well as the shortest distance of the mass to the body-wall musculature. Results: The distance from the renal mass to the body-wall musculature was significantly correlated with the total narcotics received in the periprocedural period. This measured distance did not correlate with the patient's BMI. No other relations between patient factors or tumor characteristics and peri-procedural narcotic usage were identified. Conclusion: Patients whose tumors lie close to their body-wall musculature have greater narcotic requirements in the periprocedural period. Knowledge of this correlation should result in better patient counseling and help anticipate periprocedural analgesia requirements.

Original languageEnglish (US)
Pages (from-to)606-609
Number of pages4
JournalJournal of Endourology
Volume21
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Kidney
Pain
Neoplasms
Narcotics
Body Mass Index
Analgesia
Counseling

ASJC Scopus subject areas

  • Urology

Cite this

Pain after percutaneous radiofrequency ablation of renal tumors. / Baker, Meredith; Anderson, J. Kyle; Jaffer, Omar; Trimmer, Clayton K; Cadeddu, Jeffrey A.

In: Journal of Endourology, Vol. 21, No. 6, 06.2007, p. 606-609.

Research output: Contribution to journalArticle

Baker, Meredith ; Anderson, J. Kyle ; Jaffer, Omar ; Trimmer, Clayton K ; Cadeddu, Jeffrey A. / Pain after percutaneous radiofrequency ablation of renal tumors. In: Journal of Endourology. 2007 ; Vol. 21, No. 6. pp. 606-609.
@article{e308fb108ae5436b8be29b13e54987da,
title = "Pain after percutaneous radiofrequency ablation of renal tumors",
abstract = "Background and Purpose: Most patients have minimal pain after percutaneous radiofrequency ablation (RFA) of a renal tumor. However, anecdotally, there is some variation in the amount of patient discomfort. Our goal was to identify relevant patient factors and characteristics of their renal tumors that may influence pain after percutaneous RF ablation. Patients and Methods: We performed a retrospective chart review of 59 sequential patients who received percutaneous RFA between 2001 and 2005 at a single institution. Data on patient age, sex, body mass index (BMI), and narcotic administration in the periprocedural period were available for 46 patients. Preoperative imaging (CT or MRI) was reviewed to determine tumor size and location, as well as the shortest distance of the mass to the body-wall musculature. Results: The distance from the renal mass to the body-wall musculature was significantly correlated with the total narcotics received in the periprocedural period. This measured distance did not correlate with the patient's BMI. No other relations between patient factors or tumor characteristics and peri-procedural narcotic usage were identified. Conclusion: Patients whose tumors lie close to their body-wall musculature have greater narcotic requirements in the periprocedural period. Knowledge of this correlation should result in better patient counseling and help anticipate periprocedural analgesia requirements.",
author = "Meredith Baker and Anderson, {J. Kyle} and Omar Jaffer and Trimmer, {Clayton K} and Cadeddu, {Jeffrey A}",
year = "2007",
month = "6",
doi = "10.1089/end.2006.0308",
language = "English (US)",
volume = "21",
pages = "606--609",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Pain after percutaneous radiofrequency ablation of renal tumors

AU - Baker, Meredith

AU - Anderson, J. Kyle

AU - Jaffer, Omar

AU - Trimmer, Clayton K

AU - Cadeddu, Jeffrey A

PY - 2007/6

Y1 - 2007/6

N2 - Background and Purpose: Most patients have minimal pain after percutaneous radiofrequency ablation (RFA) of a renal tumor. However, anecdotally, there is some variation in the amount of patient discomfort. Our goal was to identify relevant patient factors and characteristics of their renal tumors that may influence pain after percutaneous RF ablation. Patients and Methods: We performed a retrospective chart review of 59 sequential patients who received percutaneous RFA between 2001 and 2005 at a single institution. Data on patient age, sex, body mass index (BMI), and narcotic administration in the periprocedural period were available for 46 patients. Preoperative imaging (CT or MRI) was reviewed to determine tumor size and location, as well as the shortest distance of the mass to the body-wall musculature. Results: The distance from the renal mass to the body-wall musculature was significantly correlated with the total narcotics received in the periprocedural period. This measured distance did not correlate with the patient's BMI. No other relations between patient factors or tumor characteristics and peri-procedural narcotic usage were identified. Conclusion: Patients whose tumors lie close to their body-wall musculature have greater narcotic requirements in the periprocedural period. Knowledge of this correlation should result in better patient counseling and help anticipate periprocedural analgesia requirements.

AB - Background and Purpose: Most patients have minimal pain after percutaneous radiofrequency ablation (RFA) of a renal tumor. However, anecdotally, there is some variation in the amount of patient discomfort. Our goal was to identify relevant patient factors and characteristics of their renal tumors that may influence pain after percutaneous RF ablation. Patients and Methods: We performed a retrospective chart review of 59 sequential patients who received percutaneous RFA between 2001 and 2005 at a single institution. Data on patient age, sex, body mass index (BMI), and narcotic administration in the periprocedural period were available for 46 patients. Preoperative imaging (CT or MRI) was reviewed to determine tumor size and location, as well as the shortest distance of the mass to the body-wall musculature. Results: The distance from the renal mass to the body-wall musculature was significantly correlated with the total narcotics received in the periprocedural period. This measured distance did not correlate with the patient's BMI. No other relations between patient factors or tumor characteristics and peri-procedural narcotic usage were identified. Conclusion: Patients whose tumors lie close to their body-wall musculature have greater narcotic requirements in the periprocedural period. Knowledge of this correlation should result in better patient counseling and help anticipate periprocedural analgesia requirements.

UR - http://www.scopus.com/inward/record.url?scp=34547729174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547729174&partnerID=8YFLogxK

U2 - 10.1089/end.2006.0308

DO - 10.1089/end.2006.0308

M3 - Article

C2 - 17638554

AN - SCOPUS:34547729174

VL - 21

SP - 606

EP - 609

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 6

ER -